ASX
LCT 0.115   Last updated 5.29 am
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheet provides a summary of our current business and research pipeline.

Future development path

If the current Phase IIb trial is successful we will apply for provisional consent to treat paying patients in New Zealand and launch NTCELL® as the first disease modifying treatment for Parkinson’s disease, in 2017.

PRINT PAGE
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.